Holen Sie sich die Stockscreener-App
3.80
2.15%
0.08
Genfit Adr Aktie (GNFT) Neueste Nachrichten
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Move Higher in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Decrease Friday - MSN
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Open Week Sharply Higher in Monday Trading - MSN
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading - MSN
Genfit: New EASL-EASD-EASO guidelines include NIS2+TipRanks.com - TipRanks
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading - MSN
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary ... - GlobeNewswire
GENFIT: Historic Milestone Achieved with U.S. FDA - GlobeNewswire
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - MSN
Is Genfit (GNFT) Stock a Solid Choice Right Now - Yahoo Movies UK
European Equities Traded in the US as American Depositary Receipts Start Week Higher - MSN
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine - Ipsen
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen
Can GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect? - Yahoo New Zealand News
Ipsen und GENFIT schließen im Rahmen einer langfristigen globalen Partnerschaft eine exklusive Lizenzvereinbarung für Elafibranor ab, ein Phase-III-Asset, das für die Behandlung von primärer biliärer Cholangitis geprüft wird - Business Wire
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire
The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO - Yahoo Finance
The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana - Yahoo Finance
The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing - Yahoo Finance
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):